HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections
Status:
Completed
Trial end date:
2017-05-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, efficacy, tolerability and
pharmacokinetics of four doses of BMS-663068 with Raltegravir (RAL) + Tenofovir Disoproxil
Fumarate (TDF). At least 1 dose of BMS-663068 can be identified which is safe, well
tolerated, and efficacious when combined with RAL + TDF for treatment-experienced HIV-1
infected subjects. PHENOSENSE® is a registered trademark of Monogram Biosciences.